Retraction: Current Review of Ramosetron in the Prevention Of Postoperative Nausea and Vomiting (Curr Drug Saf, (2011) 6, 2, (122-127), 10.2174/157488611795684640);Current review of ramosetron in the prevention of postoperative nausea and vomiting

Current Drug Safety

Volumn 6, Issue 2, 2011, Pages 122-127

  Fujii, Yoshitaka ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiemetics; Complications; Ramosetron; Serotonin receptor antagonists; Vomiting

Indexed keywords

GRANISETRON; ONDANSETRON; PLACEBO; RAMOSETRON; SEROTONIN RECEPTOR;

ADULT DISEASE; ANTIEMETIC ACTIVITY; CHILDHOOD DISEASE; CHOLECYSTECTOMY; CURETTAGE; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; EMBASE; EXTRAPYRAMIDAL SYMPTOM; GYNECOLOGIC SURGERY; HEART ARRHYTHMIA; HUMAN; MEDLINE; MIDDLE EAR SURGERY; PEDIATRIC SURGERY; POSTOPERATIVE CARE; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REVIEW; SEDATION; SIDE EFFECT; STRABISMUS SURGERY; THYROIDECTOMY; TONSILLECTOMY; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

EID: 79958191847     PISSN: 15748863     EISSN: 15748863     Source Type: Journal    
DOI: None     Document Type: Erratum

References (36)

1. Watcha MF, White PF. Postoperative nausea and vomiting: its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162-70.
2. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000; 59: 213-43.
3. Fujii Y. Combination antiemetic regimens for prevention of postoperative nausea and vomiting: focus on high-risk patients. Clin Drug Invest 2002; 22: 561-54.
4. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharm Rev 1953; 5: 192-230.
5. Wang SC, Borrison HL. The vomiting center: a critical experimental analysis. Arch Neuro Psych 1950; 63: 928-41.
6. Fujii Y. The utility of antiemetics in the prevention and treatment of postoperative nausea and vomiting in patients scheduled for laparoscopic cholecystectomy. Curr Pharm Des 2005; 11: 3173-83.
7. Fujii Y. Prophylaxis of postoperative nausea and vomiting in patients scheduled for breast surgery. Clin Drug Invest 2006; 26: 427-37.
8. Bunce KT, Tyers MB. The role of 5-HT in postoperative nausea and vomiting. Br J Anaesth 1992; 69: 60S-2S.
9. Fujiwara A, Akuzawa S, Miyata K, et al. Ramosetron hydrochloride: affinity for cloned human 5-HT3 receptor antagonistic and antiemetic effect in the ferret. Kiso to Rinsho 1996; 30: 955-64.
10. White PF, Watcha MF. Has the use of meta-analysis enhanced our understanding of therapies for postoperative nausea and vomiting? Anesth Analg 1999; 88: 1200-2.
11. Noda K, Ikeda M, Yoshida O, et al. Clinical phase III study of ramosetron injection on anticancer drug, cisplatin-induced nausea and vomiting. J New Remedies Clin 1994; 43: 2241-55. [in Japanese]
12. Noda K, Ikeda M, Ichijou M, et al. Early phase II clinical study of ramosetron oral formulation in the treatment of nausea and vomiting caused by cisplatin administration. J New Remedies Clin 1996; 45: 482-90. [in Japanese]
13. Noda K, Ikeda M, Taguchi T, et al. Late phase II clinical study of ramosetron oral formulation in the treatment of nausea and vomiting caused by cisplatin administration. J New Remedies Clin 1996; 45: 1309-21. [in Japanese]
14. Fujii Y, Saitoh Y, Tanaka H, et al. Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery. Anesth Analg 2000; 90: 472-5.
15. Fujii Y, Tanaka H, Somekawa Y. A randomized, double-blind, placebo-controlled trial of ramosetron for preventing nausea and vomiting during ternimation of pregnancy. Int J Obstet Anesth 2004; 13: 15-8.
16. Fujii Y, Uemura A, Tanaka H. Prophylaxis of nausea and vomiting after laparoscopic cholecystectomy with ramosetron: randomised controlled trial. Eur J Surg 2002; 168: 583-6.
17. Fujii Y, Tanaka H. Randomized, double-blind, placebo-controlled, dose-finding study of the antiemetic effects and tolerability of ramosetron in aduls undergoing middle ear surgery. Clin Ther 2003; 25: 3100-8.
18. Fujii Y, Tanaka H. Double-blind, placebo-controlled, dose-ranging study of ramosetron for the prevention of nausea and vomiting after thyroidectomy. Clin Ther 2002; 24: 1148-53.
19. Fujii Y, Tanaka H. Prevention of nausea and vomiting with ramosetron after total hip replacement. Clin Drug Invest 2003; 23: 405-9.
20. Lee D, Kim Y, Shin JW, et al. The effect of oral and IV ramosetron on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy with total intravenous anesthesia. J Anesth 2009; 23: 46-50.
21. Lee SY, Lee JY, Park SY, et al. Prophylactic antiemetic efficacy of granisetron or ramosetron in patients undergoing thyroidectomy. Asian J Surg 2002; 25: 309-14.
22. Fujii Y, Saitoh Y, Tanaka H, et al. Comparison of ramosetron and granisetron for preventing postoperative nausea and vomiting after gynecologic surgery. Anesth Analg 1999; 89: 476-9.
23. Fujii Y, Saitoh Y, Tanaka H, et al. Ramosetron vs granisetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Can J Anesth 1999; 46: 991-3.
24. Fujii Y, Tanaka H, Kobayashi N. Prevention of nausea and vomiting after middle ear surgery: granisetron vs ramosetron. Laryngoscope 1999; 109: 1988-90.
25. Fujii Y, Tanaka H, Kawasaki T. Benefits and risks of granisetron versus ramosetron for nausea and vomiting after breast surgery: a randomized, double-blinded, placebo-controlled trial. Am J Ther 2004; 11: 278-82.
26. Fujii Y, Tanaka H. Comparison of granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy. Clin Ther 2002; 24: 766-72.
27. Hahm TS, Ko JS, Choi SJ, et al. Comaprison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at high-risk for postoperative nausea and vomiting after total knee replacement. Anaesthesia 2010; 65: 500-4.
28. Kim SI, Kim SC, Baek YH, et al. Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery. Br J Anaesth 2009; 103: 549-53.
29. Ryu J, So Y-M, Hwang J, et al. Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Surg Endosc 2010; 24: 812-7.
30. Fujii Y, Tanaka H, Ito M. A randomized clinical trial of a single dose of ramosetron for the prevention of vomiting after strabismus surgery in children: a dose-ranging study. Arch Ophthalmol 2005; 123: 25-8.
31. Fujii Y, Tanaka H. Results of a prospective, randomoized, double-blind, placebo-controlled, dose-ranging trial to determine the effective dose of ramosetron for the prevention of vomiting after tonsillectomy in children. Clin Ther 2003; 25: 3135-42.
32. Fujii Y, Tanaka H, Ito M. Ramosetron compared with granisetron for the prevention of vomiting following strabismus surgery in children. Br J Ophthalmol 2001; 85: 670-2.
33. Fujii Y, Saitoh Y, Kobayashi N. Prevention of vomiting after tonsillectomy in children: granisetron versus ramosetron. Laryngoscope 2001; 111: 255-8.
34. Kasinath NS, Malak O, Tetzlaft J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anesth 2003; 50: 229-31.
35. Baguley WA, Hay WT, Mackie KP, et al. Cardiac dysrhythmias associatd with intravenous administration of ondansetron and metoclopramide. Anesth Analg 1997; 84: 1380-1.
36. McCormic CG. FDA allert: current FDA report on droperidol status and basis for"Black Box"warning. ASA Newslett 2002; 66: 19.